Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 100.82 Million USD | 43.31% |
| 2022 | 70.35 Million USD | 26.35% |
| 2021 | 55.68 Million USD | 30.52% |
| 2020 | 42.66 Million USD | 30.52% |
| 2019 | 32.68 Million USD | 24.95% |
| 2018 | 26.16 Million USD | 37.18% |
| 2017 | 19.07 Million USD | 37.72% |
| 2016 | 13.84 Million USD | 15.43% |
| 2015 | 11.99 Million USD | -48.88% |
| 2014 | 23.46 Million USD | 23118.16% |
| 2013 | 101.07 Thousand USD | 22947.04% |
| 2012 | 438.56 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 34.07 Million USD | 16.35% |
| 2024 Q2 | 33.97 Million USD | -0.28% |
| 2024 Q3 | 36.55 Million USD | 7.58% |
| 2023 Q1 | 20.53 Million USD | 1.25% |
| 2023 Q3 | 27.26 Million USD | 14.85% |
| 2023 Q2 | 23.74 Million USD | 15.6% |
| 2023 Q4 | 29.28 Million USD | 7.41% |
| 2023 FY | 100.53 Million USD | 42.9% |
| 2022 Q4 | 20.28 Million USD | 25.23% |
| 2022 Q2 | 17.63 Million USD | 8.53% |
| 2022 Q1 | 16.24 Million USD | 29.86% |
| 2022 FY | 70.35 Million USD | 26.35% |
| 2022 Q3 | 16.19 Million USD | -8.14% |
| 2021 FY | 55.68 Million USD | 30.52% |
| 2021 Q3 | 13.4 Million USD | -13.76% |
| 2021 Q1 | 14.22 Million USD | 26.3% |
| 2021 Q2 | 15.54 Million USD | 9.23% |
| 2021 Q4 | 12.51 Million USD | -6.66% |
| 2020 FY | 42.66 Million USD | 30.52% |
| 2020 Q4 | 11.26 Million USD | 14.45% |
| 2020 Q3 | 9.84 Million USD | -7.19% |
| 2020 Q2 | 10.6 Million USD | -3.12% |
| 2020 Q1 | 10.94 Million USD | 23.39% |
| 2019 FY | 32.68 Million USD | 24.95% |
| 2019 Q4 | 8.87 Million USD | 19.28% |
| 2019 Q3 | 7.43 Million USD | -22.26% |
| 2019 Q2 | 9.56 Million USD | 40.6% |
| 2019 Q1 | 6.8 Million USD | -3.28% |
| 2018 Q2 | 6.92 Million USD | 44.12% |
| 2018 FY | 26.16 Million USD | 37.18% |
| 2018 Q4 | 7.03 Million USD | -4.83% |
| 2018 Q3 | 7.39 Million USD | 6.77% |
| 2018 Q1 | 4.8 Million USD | 8.53% |
| 2017 Q4 | 4.42 Million USD | -5.63% |
| 2017 Q3 | 4.69 Million USD | -5.84% |
| 2017 Q2 | 4.98 Million USD | 0.28% |
| 2017 Q1 | 4.96 Million USD | 32.94% |
| 2017 FY | 19.07 Million USD | 37.72% |
| 2016 Q3 | 3.26 Million USD | -8.77% |
| 2016 FY | 13.84 Million USD | 15.43% |
| 2016 Q1 | 3.26 Million USD | -29.28% |
| 2016 Q2 | 3.57 Million USD | 9.51% |
| 2016 Q4 | 3.73 Million USD | 14.5% |
| 2015 Q1 | 461.04 Thousand USD | 30.4% |
| 2015 Q2 | 2.62 Million USD | 469.78% |
| 2015 Q4 | 4.62 Million USD | 7.74% |
| 2015 Q3 | 4.28 Million USD | 63.24% |
| 2015 FY | 11.99 Million USD | -48.88% |
| 2014 Q1 | 209.73 Thousand USD | 313.21% |
| 2014 Q2 | 21.75 Million USD | 10272.82% |
| 2014 Q3 | 1.14 Million USD | -94.72% |
| 2014 Q4 | 353.56 Thousand USD | -69.23% |
| 2014 FY | 23.46 Million USD | 23118.16% |
| 2013 Q1 | 3190.00 USD | -97.09% |
| 2013 Q3 | 50.75 Thousand USD | 199.35% |
| 2013 Q4 | 50.75 Thousand USD | 0.0% |
| 2013 Q2 | 16.95 Thousand USD | 431.54% |
| 2013 FY | 101.07 Thousand USD | 22947.04% |
| 2012 Q4 | 109.64 Thousand USD | 0.0% |
| 2012 FY | 438.56 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 59.23% |
| Dynavax Technologies Corporation | 219.14 Million USD | 53.991% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 80.94% |
| Perrigo Company plc | 1.52 Billion USD | 93.404% |
| Illumina, Inc. | 3.81 Billion USD | 97.356% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.017% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 77.643% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.752% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 95.089% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 16.435% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 96.419% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -125.73% |
| Waters Corporation | 943.51 Million USD | 89.314% |
| Biogen Inc. | 5.2 Billion USD | 98.063% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 55.909% |
| Evolus, Inc. | 189.75 Million USD | 46.866% |
| Adicet Bio, Inc. | 152.03 Million USD | 33.683% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 29.226% |
| bluebird bio, Inc. | 240.23 Million USD | 58.029% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 62.917% |
| FibroGen, Inc. | 398.11 Million USD | 74.674% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 95.233% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -624.871% |
| Homology Medicines, Inc. | 9.87 Million USD | -921.033% |
| Geron Corporation | 70.44 Million USD | -43.137% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 94.399% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 76.423% |
| Myriad Genetics, Inc. | 600.1 Million USD | 83.198% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 81.72% |
| Zoetis Inc. | 2.76 Billion USD | 96.353% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -107.882% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 90.745% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 94.226% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 97.888% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -157.52% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 87.067% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 63.428% |
| Verastem, Inc. | 92.08 Million USD | -9.495% |
| Nektar Therapeutics | 190.9 Million USD | 47.184% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 78.834% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -730.467% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 92.591% |
| OPKO Health, Inc. | 574.68 Million USD | 82.455% |
| Exelixis, Inc. | 1.58 Billion USD | 93.646% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 93.684% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 72.647% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -80.836% |
| uniQure N.V. | 285.08 Million USD | 64.633% |
| Imunon, Inc. | 21.03 Million USD | -379.434% |
| Blueprint Medicines Corporation | 722.86 Million USD | 86.052% |
| Insmed Incorporated | 949.26 Million USD | 89.378% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 66.314% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 75.336% |
| TG Therapeutics, Inc. | 198.47 Million USD | 49.199% |
| Incyte Corporation | 1.19 Billion USD | 91.531% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 90.342% |